Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma.
- 2015-10-27
Published in:
- Chemotherapy. - 2014
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Brain Neoplasms
Carboplatin
Disease Progression
Etoposide
Female
Glioma
Humans
Male
Middle Aged
Retrospective Studies
English
BACKGROUND
Treatment of recurrent anaplastic glioma and glioblastoma remains a particular challenge in neurooncology. The lack of controlled trials results in poor evidence for all therapeutic options. Upon recurrence, many patients are treated with bevacizumab or one of the frequently used nitrosoureas such as lomustine. However, patients who still present in overall good condition after failure of multiple lines of therapy may ask for additional therapy.
METHODS
Here, we report our experience with the use of carboplatin in combination with etoposide as fourth- or fifth-line therapy in patients with progressive high-grade glioma.
RESULTS
The median Karnofsky performance status at the beginning of treatment was 80%. The median progression-free survival (PFS) was 2.5 months. PFS at 6 months was 0%. Administration of carboplatin and etoposide was associated with grade 3 or 4 hematotoxicity in 8 of 12 patients.
CONCLUSION
Carboplatin in combination with etoposide has an unfavorable risk-benefit profile in heavily pretreated glioma patients.
Treatment of recurrent anaplastic glioma and glioblastoma remains a particular challenge in neurooncology. The lack of controlled trials results in poor evidence for all therapeutic options. Upon recurrence, many patients are treated with bevacizumab or one of the frequently used nitrosoureas such as lomustine. However, patients who still present in overall good condition after failure of multiple lines of therapy may ask for additional therapy.
METHODS
Here, we report our experience with the use of carboplatin in combination with etoposide as fourth- or fifth-line therapy in patients with progressive high-grade glioma.
RESULTS
The median Karnofsky performance status at the beginning of treatment was 80%. The median progression-free survival (PFS) was 2.5 months. PFS at 6 months was 0%. Administration of carboplatin and etoposide was associated with grade 3 or 4 hematotoxicity in 8 of 12 patients.
CONCLUSION
Carboplatin in combination with etoposide has an unfavorable risk-benefit profile in heavily pretreated glioma patients.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1159/000440678
- PMID 26496463
- Persistent URL
- https://sonar.ch/global/documents/263452
Statistics
Document views: 27
File downloads:
- Full-text: 0